SCHEMBL6935203

SCHEMBL6935203

CC(C)(C)c1ccc(N(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.50
ALDH1A1 P00352 4/20 0.50
CYP2D6 P10635 2/20 0.50
MAPT P10636 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP3A4 P08684 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
RAB9A P51151 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 1/20 0.44
LMNA P02545 2/20 0.42
TYR P14679 1/20 0.42
CRHBP P24387 1/20 0.42
ATM Q13315 1/20 0.42
CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13721510 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL14069614 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL13133424 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL9312582 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL13720599 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL14163852 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL14163839 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL13720556 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL15746013 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1
SCHEMBL19996391 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1CYP2D6MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113130788-B Composite material, thin film, and quantum dot light emitting diode TCL科技集团股份有限公司 2022-04-12 CN claimed
CN-113130788-A Composite material, thin film, and quantum dot light emitting diode TCL集团股份有限公司 2021-07-16 CN claimed
CN-111244200-A Light emitting device, display device, method for manufacturing display device, and power generation device TCL集团股份有限公司 2020-06-05 CN claimed
CN-111244303-A Light emitting device, display device, method for manufacturing display device, and power generation device TCL集团股份有限公司 2020-06-05 CN claimed
US-12041848-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2024-07-16 US disclosed
US-12029111-B2 Oxygen heterocyclic compound, application thereof and electronic device using the same WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-07-02 US disclosed
US-12029111-B2 Oxygen heterocyclic compound, application thereof and electronic device using the same WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-07-02 US disclosed
US-11708328-B2 Organic electroluminescent compound and organic electroluminescent device comprising the same ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. 2023-07-25 US disclosed
US-11708328-B2 Organic electroluminescent compound and organic electroluminescent device comprising the same ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. 2023-07-25 US disclosed
US-20230151270-A1 Aggregation-Induced Emission Polymer, Preparation Method and Application Thereof QINGDAO AGRICULTURAL UNIVERSITY (CN) 2023-05-18 US disclosed
US-20230151270-A1 Aggregation-Induced Emission Polymer, Preparation Method and Application Thereof QINGDAO AGRICULTURAL UNIVERSITY (CN) 2023-05-18 US disclosed
US-20230041564-A1 OXYGEN HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND ELECTRONIC DEVICE USING THE SAME WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2023-02-09 US disclosed
US-20070232811-A1 STERICALLY HINDERED PI-BRIDGE NONLINEAR OPTICAL CHROMOPHORES, PROCESSES INCLUDING SAME, AND DEVICES THEREFROM LUMERA CORPORATION (US) 2007-10-04 US disclosed
US-7206111-B2 Sterically hindered PI-bridge nonlinear optical chromophores, processes including same, and devices therefrom LUMERA CORPORATION (US) 2007-04-17 US disclosed
US-7196155-B2 Process for preparing poly(arylene ethers) with pendant crosslinkable groups LUMERA CORPORATION (US) 2007-03-27 US disclosed
US-20070032628-A1 CROSSLINKED COMPOSITIONS COMPRISING A POLY(ARYLENE ETHER) AND A NONLINEAR OPTICAL CHROMOPHORE, AND DEVICES INCORPORATING SAME SILICON VALLEY BANK 2007-02-08 US disclosed
EP-1167372-B1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO PERFUMERY CO LTD (JP) 2003-12-10 EP disclosed
US-6455720-B1 AS CATALYSTS TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-09-24 US disclosed
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-05-16 US disclosed
EP-1167372-A1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst Takasago International Corporation (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst DDT, PDCD11, PLD2 L3MBTL1 1659/4885ALDH1A1 2369/4885CYP2D6 309/4885
US-12029111-B2 Oxygen heterocyclic compound, application thereof and electronic device using the same AOC2, AOX1, TYR L3MBTL1 3116/4885ALDH1A1 178/4885CYP2D6 174/4885
US-12041848-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, NR2E3 L3MBTL1 622/4885ALDH1A1 242/4885CYP2D6 502/4885
US-11708328-B2 Organic electroluminescent compound and organic electroluminescent device comprising the same ELAVL1, TERT, VDAC2 L3MBTL1 239/4885ALDH1A1 838/4885CYP2D6 4019/4885
US-20070232811-A1 STERICALLY HINDERED PI-BRIDGE NONLINEAR OPTICAL CHROMOPHORES, PROCESSES INCLUDING SAME, AND DEVICES THEREFROM FARS2, ETFA, ETFB L3MBTL1 3683/4885ALDH1A1 1458/4885CYP2D6 2721/4885
US-20230041564-A1 OXYGEN HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND ELECTRONIC DEVICE USING THE SAME AOC2, AOX1, TYR L3MBTL1 3116/4885ALDH1A1 178/4885CYP2D6 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.